Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $137.00

Axsome Therapeutics (NASDAQ:AXSM) had its price target hoisted by Mizuho from $122.00 to $137.00 in a research report released on Monday,Benzinga reports. Mizuho currently has an outperform rating on the stock.

Several other equities research analysts have also recently issued reports on AXSM. Robert W. Baird lifted their price objective on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $139.00 price target on shares of Axsome Therapeutics in a research note on Wednesday, January 29th. Needham & Company LLC reaffirmed a “buy” rating and issued a $133.00 price objective on shares of Axsome Therapeutics in a research note on Monday, January 13th. HC Wainwright upped their price target on shares of Axsome Therapeutics from $180.00 to $190.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Finally, William Blair reissued an “outperform” rating on shares of Axsome Therapeutics in a research note on Friday, January 24th. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat.com, Axsome Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $134.00.

Axsome Therapeutics Stock Up 1.0 %

Shares of AXSM stock opened at $114.00 on Monday. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The stock has a market cap of $5.52 billion, a P/E ratio of -17.46 and a beta of 1.05. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $114.00. The company has a 50 day simple moving average of $94.37 and a two-hundred day simple moving average of $91.43.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The business had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. During the same quarter in the prior year, the business posted ($1.32) EPS. On average, research analysts expect that Axsome Therapeutics will post -4.72 earnings per share for the current year.

Hedge Funds Weigh In On Axsome Therapeutics

A number of institutional investors have recently modified their holdings of AXSM. FMR LLC boosted its holdings in shares of Axsome Therapeutics by 20.6% in the third quarter. FMR LLC now owns 1,088,087 shares of the company’s stock valued at $97,786,000 after purchasing an additional 185,951 shares during the period. Geode Capital Management LLC raised its holdings in shares of Axsome Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 908,459 shares of the company’s stock valued at $81,659,000 after acquiring an additional 23,564 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Axsome Therapeutics by 1.1% in the 3rd quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock valued at $66,750,000 after purchasing an additional 8,125 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Axsome Therapeutics by 4.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 322,596 shares of the company’s stock worth $28,992,000 after purchasing an additional 12,778 shares during the period. Finally, Loomis Sayles & Co. L P boosted its stake in shares of Axsome Therapeutics by 11.0% during the third quarter. Loomis Sayles & Co. L P now owns 298,586 shares of the company’s stock valued at $26,834,000 after purchasing an additional 29,497 shares in the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.